Despite the fact that there have not yet been any large clinical trials focusing on mGluR5 in epilepsy, selective group I mGluR antagonists were explored for their anticonvulsant effects in rodent models of epilepsy by Chapman et al., 2000, and Yan et al., 2005 [49,50]. This evidence concerns the gene GRM5 and epilepsy.